RU2002106399A - MOXIFLOXACIN COMPOSITIONS CONTAINING SODIUM SALT - Google Patents

MOXIFLOXACIN COMPOSITIONS CONTAINING SODIUM SALT

Info

Publication number
RU2002106399A
RU2002106399A RU2002106399/15A RU2002106399A RU2002106399A RU 2002106399 A RU2002106399 A RU 2002106399A RU 2002106399/15 A RU2002106399/15 A RU 2002106399/15A RU 2002106399 A RU2002106399 A RU 2002106399A RU 2002106399 A RU2002106399 A RU 2002106399A
Authority
RU
Russia
Prior art keywords
moxifloxacin
hydrochloride
aqueous composition
sodium chloride
amount
Prior art date
Application number
RU2002106399/15A
Other languages
Russian (ru)
Other versions
RU2260429C2 (en
RU2260429C9 (en
Inventor
Бернд Кюн
Ханс-Фридрих МАЛЕР
Михаэль АЙЗЕЛЕ
Original Assignee
Байер Акциенгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19937116A external-priority patent/DE19937116A1/en
Application filed by Байер Акциенгезелльшафт filed Critical Байер Акциенгезелльшафт
Publication of RU2002106399A publication Critical patent/RU2002106399A/en
Publication of RU2260429C2 publication Critical patent/RU2260429C2/en
Application granted granted Critical
Publication of RU2260429C9 publication Critical patent/RU2260429C9/en

Links

Claims (11)

1. Водный состав, содержащий от 0,04 до 0,4% (м/о) (считая на количество моксифлоксацина) моксифлоксацин-гидрохлорида и от 0,4 до 0,9% (м/о) хлорида натрия.1. An aqueous composition containing from 0.04 to 0.4% (m / v) (counting the amount of moxifloxacin) moxifloxacin-hydrochloride and from 0.4 to 0.9% (m / o) sodium chloride. 2. Водный состав согласно п.1, содержащий от 0,08 до 0,32% (м/о) (считая на количество моксифлоксацина) моксифлоксацин-гидрохлорида.2. The aqueous composition according to claim 1, containing from 0.08 to 0.32% (m / v) (counting the amount of moxifloxacin) moxifloxacin hydrochloride. 3. Водный состав согласно п.1 или 2, содержащий от 0,1 до 0,2% (м/о) (считая на количество моксифлоксацина) моксифлоксацин-гидрохлорида.3. The aqueous composition according to claim 1 or 2, containing from 0.1 to 0.2% (m / v) (counting the amount of moxifloxacin) moxifloxacin hydrochloride. 4. Водный состав согласно пп.1, 2 или 3, содержащий от 0,5 до 0,9% (м/о) хлорида натрия.4. The aqueous composition according to claims 1, 2 or 3, containing from 0.5 to 0.9% (m / v) sodium chloride. 5. Водный состав согласно пп.1, 2, 3 или 4, содержащий от 0,7 до 0,9% (м/о) хлорида натрия.5. The aqueous composition according to claims 1, 2, 3 or 4, containing from 0.7 to 0.9% (m / v) sodium chloride. 6. Способ получения водного состава моксифлоксацин-гидрохлорида, по которому вначале получают раствор моксифлоксацин-гидрохлорида в воде, а затем добавляют хлорид натрия и растворяют.6. A method of obtaining an aqueous composition of moxifloxacin hydrochloride, according to which a solution of moxifloxacin hydrochloride in water is first prepared, and then sodium chloride is added and dissolved. 7. Способ получения водного состава моксифлоксацин-гидрохлорида согласно п.1, отличающийся тем, что раствор моксифлоксацин-гидрохлорида в воде с концентрацией моксифлоксацин-гидрохлорида (считая на количество моксифлоксацина) более, чем от 0,4 до 2,4% (м/о) смешивают с водным раствором, содержащим хлорид натрия.7. The method of obtaining the aqueous composition of moxifloxacin hydrochloride according to claim 1, characterized in that the solution of moxifloxacin hydrochloride in water with a concentration of moxifloxacin hydrochloride (based on the amount of moxifloxacin) is more than 0.4 to 2.4% (m / o) mixed with an aqueous solution containing sodium chloride. 8. Применение водного раствора моксифлоксацин-гидрохлорида в воде с концентрацией моксифлоксацин-гидрохлорида (считая на количество моксифлоксацина) более, чем от 0,4 до 2,4% (м/о) для получения лекарственного средства для парентерального введения.8. The use of an aqueous solution of moxifloxacin-hydrochloride in water with a concentration of moxifloxacin-hydrochloride (counting the amount of moxifloxacin) more than from 0.4 to 2.4% (m / v) to obtain a drug for parenteral administration. 9. Комбинированный препарат, содержащий водный раствор моксифлоксацин-гидрохлорида в воде с концентрацией моксифлоксацин-гидрохлорида (считая на количество моксифлоксацина) более, чем от 0,4 до 2,4% (м/о) и водный раствор хлорида натрия, изолированные друг от друга.9. A combined preparation containing an aqueous solution of moxifloxacin hydrochloride in water with a concentration of moxifloxacin hydrochloride (counting the amount of moxifloxacin) more than 0.4 to 2.4% (m / v) and an aqueous solution of sodium chloride, isolated from each other friend. 10. Водный состав согласно одному из пп.1-5 для применения в качестве лекарственного средства.10. The aqueous composition according to one of claims 1 to 5 for use as a medicine. 11. Применение состава согласно пп.1-5 для получения лекарственного средства для профилактики или лечения бактериальных инфекций у людей или животных.11. The use of the composition according to claims 1-5 for the manufacture of a medicament for the prevention or treatment of bacterial infections in humans or animals.
RU2002106399/15A 1999-08-06 2000-07-25 Sodium chloride-containing moxifloxacin compositions RU2260429C9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937116A DE19937116A1 (en) 1999-08-06 1999-08-06 Moxifloxacin saline formulation
DE19937116.4 1999-08-06

Publications (3)

Publication Number Publication Date
RU2002106399A true RU2002106399A (en) 2003-12-27
RU2260429C2 RU2260429C2 (en) 2005-09-20
RU2260429C9 RU2260429C9 (en) 2006-03-27

Family

ID=7917417

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002106399/15A RU2260429C9 (en) 1999-08-06 2000-07-25 Sodium chloride-containing moxifloxacin compositions

Country Status (40)

Country Link
US (1) US6548079B1 (en)
EP (1) EP1206281B1 (en)
JP (1) JP5522877B2 (en)
KR (1) KR100735788B1 (en)
CN (1) CN1246039C (en)
AR (1) AR025001A1 (en)
AT (1) ATE270104T1 (en)
AU (1) AU771058B2 (en)
BG (1) BG65304B1 (en)
BR (1) BRPI0013010B8 (en)
CA (1) CA2378424C (en)
CO (1) CO5190677A1 (en)
CU (1) CU23367A3 (en)
CZ (1) CZ298768B6 (en)
DE (2) DE19937116A1 (en)
DK (1) DK1206281T3 (en)
EE (1) EE04771B1 (en)
ES (1) ES2223549T3 (en)
GT (1) GT200000123A (en)
HK (1) HK1049615B (en)
HN (1) HN2000000115A (en)
HR (1) HRP20020198B1 (en)
HU (1) HU229571B1 (en)
IL (2) IL147553A0 (en)
MA (1) MA25427A1 (en)
MX (1) MXPA02001254A (en)
MY (1) MY125356A (en)
NO (1) NO320743B1 (en)
NZ (1) NZ516969A (en)
PE (1) PE20010400A1 (en)
PL (1) PL198132B1 (en)
PT (1) PT1206281E (en)
RU (1) RU2260429C9 (en)
SI (1) SI1206281T1 (en)
SK (1) SK285650B6 (en)
TW (1) TWI238719B (en)
UA (1) UA72268C2 (en)
UY (1) UY26269A1 (en)
WO (1) WO2001010465A1 (en)
ZA (1) ZA200200215B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (en) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin saline formulation
DE10218328A1 (en) * 2002-03-05 2003-09-25 Humboldt Uni Zu Berlin Medizin Preventive therapy for acute stroke
US20040197408A1 (en) * 2002-12-30 2004-10-07 Angiotech International Ag Amino acids in micelle preparation
WO2006015545A1 (en) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Gelatin capsule of moxifloxacin and method for its prepartion
JO3270B1 (en) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv Quinoline Derivatives as Antibacterial Agents
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline Derivatives as Antibacterial Agents
DE102006031175A1 (en) * 2006-07-06 2008-01-10 Bayer Healthcare Ag Aqueous drug formulation of 4 - [((4-carboxybutyl) - (2 [(4-phenethyl-benzyl) oxy] -phenethyl) amino) methyl] benzoic acid
US7537532B2 (en) * 2007-05-16 2009-05-26 Young Carl D Handle for implement and method
CN101787022B (en) * 2009-10-09 2012-08-22 浙江医药股份有限公司新昌制药厂 Quinoline carboxylic acid hydrochloride-hydrate novel crystal form, and preparation method thereof
WO2011086577A2 (en) * 2010-01-12 2011-07-21 Msn Laboratories Limited Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts
CN101836950A (en) * 2010-03-12 2010-09-22 陕西合成药业有限公司 Moxifloxacin hydrochloride glucose injection and preparation method and use thereof
CN103919779B (en) * 2010-09-10 2016-02-10 杭州民生药业有限公司 A kind of pharmaceutical composition containing Moxifloxacin
CN102093349B (en) * 2011-01-17 2012-03-07 南京新港医药有限公司 Method for performing industrialized production on moxifloxacin hydrochloride
CN102100666B (en) * 2011-01-17 2012-07-18 南京新港医药有限公司 New moxifloxacin hydrochloride injection
CN102688183B (en) * 2011-03-21 2016-04-06 重庆医药工业研究院有限责任公司 A kind of stable moxifloxacin hydrochloride injection
KR101435244B1 (en) * 2011-04-12 2014-08-29 씨제이헬스케어 주식회사 Moxifloxacin formulation and method of preparing the same
KR101327904B1 (en) * 2011-08-16 2013-11-13 대한약품공업 주식회사 Formulation for parenteral injection of moxifloxacin hydrochloride
RU2472507C1 (en) * 2012-02-01 2013-01-20 Закрытое акционерное общество "Брынцалов-А" Moxifloxacin aqueous formulation for parenteral introduction
CN102600093B (en) * 2012-04-11 2013-06-05 南京优科生物医药有限公司 Moxifloxacin tablet and preparation method thereof
GR1008168B (en) 2013-03-14 2014-04-08 "Φαρματεν Α.Β.Ε.Ε.", Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof
CN103191056B (en) * 2013-04-28 2014-10-22 南京海融医药科技有限公司 Oral liquid preparation of moxifloxacin as well as preparation method and application thereof
WO2015093669A1 (en) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 Aqueous formulation of moxifloxacin and preparation method therefor
CN103976944A (en) * 2014-05-16 2014-08-13 成都青山利康药业有限公司 Moxifloxacin hydrochloride sodium chloride injection
CN104771359A (en) * 2015-04-02 2015-07-15 南京正大天晴制药有限公司 Steady moxifloxacin hydrochloride injection
CN105640876B (en) * 2016-01-07 2019-04-12 天津红日药业股份有限公司 A kind of preparation process of moxifloxacin hydrochloride injection
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3578182A1 (en) * 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations containing triazinones and iron with a low amount of free iron ions
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
CN111388415A (en) * 2020-03-19 2020-07-10 石家庄四药有限公司 Moxifloxacin hydrochloride sodium chloride injection and preparation method thereof
EP4238552A1 (en) 2020-10-29 2023-09-06 Taejoon Pharmaceutical Co., Ltd. Ophthalmic composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537761A1 (en) 1985-10-24 1987-04-30 Bayer Ag INFUSION SOLUTIONS OF 1-CYCLOPROPYL-6-FLUOR-1,4-DIHYDRO-4-OXO-7- (1-PIPERAZINYL) -QUINOLINE-3-CARBONIC ACID
JPH01258620A (en) * 1988-04-08 1989-10-16 Dai Ichi Seiyaku Co Ltd Local pharmaceutical for otopathy
DE3906365A1 (en) * 1988-07-15 1990-01-18 Bayer Ag 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM
WO1990013542A1 (en) * 1989-04-28 1990-11-15 Daiichi Pharmaceutical Co., Ltd. Anti-hiv drug
DK0507851T3 (en) 1989-12-29 1997-08-25 Abbott Lab Quinolone-matalion acid complexes
US5084276A (en) 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
FR2681863B1 (en) 1991-09-27 1995-02-03 Rhone Dpc Europ SOLUTION OF SPARFLOXACIN, ITS PREPARATION AND SALT CONSTITUTING IT.
DE4306417A1 (en) * 1993-03-02 1994-09-08 Grace Gmbh Device and method for burning oxidizable components in a carrier gas to be cleaned
CA2152828A1 (en) * 1993-03-16 1994-07-07 Shin-Ichi Uesato 8-methoxy-quinolonecarboxylic acid derivatives
KR960000223A (en) 1994-06-08 1996-01-25 김정순 Aqueous solution containing novel pyridone carboxylic acid compound and preparation method thereof
ATE212551T1 (en) 1995-12-21 2002-02-15 Pfizer INJECTABLE QUINOLONE FORMULATIONS
JPH1192375A (en) * 1997-09-25 1999-04-06 Morinaga Milk Ind Co Ltd Antibacterial agent capable of enhancing antibacterial activity of new quinolone-based antibacterial drug
AR020661A1 (en) * 1998-09-30 2002-05-22 Alcon Lab Inc A PHARMACEUTICAL COMPOSITION TOPICA OFTALMICA, OTICA OR NASAL AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
UA72483C2 (en) * 1998-11-10 2005-03-15 Moxifloxacin-containing pharmaceutical preparation and method for its manufacture
DE19937115A1 (en) * 1999-08-06 2001-02-08 Bayer Ag Aqueous drug formulation of moxifloxacin or salts thereof
DE19937116A1 (en) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin saline formulation

Similar Documents

Publication Publication Date Title
RU2002106399A (en) MOXIFLOXACIN COMPOSITIONS CONTAINING SODIUM SALT
EA200400777A1 (en) PHARMACEUTICAL COMPOSITIONS PLATINUM CONNECTIONS
JP2003506416A5 (en)
JP2010525033A5 (en)
KR940005636A (en) Triazolylthiomethylthio cephalosporin hydrochloride, its hydrate crystals and preparation method thereof
NO20063277L (en) Pharmaceutical composition of vinflunine intended for parenteral administration, preparation and use thereof
CA1290690C (en) Method of reducing the swelling or pain associated with antibiotics compositions
US6410543B1 (en) Method of producing a concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution
RU95101385A (en) Products containing g-csf and tnf-binding protein
WO2014165087A1 (en) Mdr method and products for treating hiv/aids
JP2006523723A (en) Method of modulating and introducing pharmaceutically active compounds
RU2007105450A (en) TREATMENT AND PREVENTION OF DISEASES AND INFECTIONS OF PIGS AND Poultry
RU2006109966A (en) YANTASTIM-S DRUG FOR THERAPY AND PREVENTION OF ANIMAL INFECTIOUS DISEASES
RU2360667C2 (en) Antibacterial medication for treatment and prevention of gastro-intestinal diseases in animals
CA1336491C (en) Antiviral pharmaceutical composition
TR200201654T2 (en) Benzamidine derivatives.
RU2002107675A (en) MEDICINES CONTAINING XENOGENOUS OLIGO OR / AND POLYRIBONUCLEOTIDES
Clyde et al. Therapeutic trials of chloroquine silicate in Tanganyika
ATE443452T1 (en) METHOD FOR PRODUCING EDIBLE COMPOSITIONS WITH ANTIBACTERIAL ACTIVE INGREDIENTS
JP3212364B2 (en) New royal jelly formulation
RU2003108517A (en) METHOD FOR TREATING COLIBACTERIOSIS AND SALMONELLOSIS IN PIGLIES
RU2333747C1 (en) Composition for treatment of animal purulent peritonitis
RU2003130984A (en) METHOD FOR TREATING TUBERCULOSIS AND DRUG FOR INHALATIONS DURING ITS IMPLEMENTATION
RU2002104753A (en) Method for the prevention and treatment of cattle leukemia
RU99106729A (en) NEW MEDICINAL FORM OF CEPHALOSPORIN ANTIBIOTIC FOR Parenteral Administration